Virogentics, Inc to Introduce a Dietary Supplement Offers Additional Information on ITV-1 And Diabetic Clinical Trials

ALLEN, TX / ACCESSWIRE / July 6, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).

Virogentics, Inc. ("VIRO") a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, announced today its plan to introduce a dietary supplement, + Liver Rescue™, a liver and detox beverage. The product is currently being sold in Europe. VIRO has the exclusive license for distribution in North America. The packaging/label is being submitted to the FDA for approval before beginning marketing and distribution.

VIRO continues to make progress toward the projected August administering of the patented immunotherapy ITV-1 treatment to volunteers under a fast-track protocol supervised by Neuro Pharma Ltd - Rwanda, at HEAL Africa Hospitals, GOMA, PRC and Panzi Hospital, Bukavu, DRC. Approval of the protocol criteria is the final step necessary to meet the requirements to inject the African the HIV/Aids volunteer victims, which is expected to be received imminently. VIRO's partner has arranged for the health insurance for the volunteers and has paid all necessary costs for the issuance of the permits and manufacturing associated with the African Clinical trials.

The clinical trials will be headed by Dr. Amogne Wondwossen, Associate Professor in Internal Medicine and Infectious diseases (MD, PhD) Addis Ababa University College of Health Sciences, School of Medicine, Internal Medicine Department, Honorary full Professor in Molecular and Clinical Medicine, University of Dundee, Scotland.

VIRO has also completed the arrangements for the final payment for the BTS toxicity report that will allow the clinical trials on ITV-1's impact on the blood sugar levels in diabetic patients to proceed.

The Company, assisted by Sagaliam Acquisition Corp. ("NASDAQ:SAGA"), is preparing a supplemental information filing to give insight into the SAGA transaction and offer explanations to some of the shareholder questions surrounding the sale of ENZC's operating subsidiaries, Virogentics ("VIRO") and Biogenysis ("BGEN"). The filing is expected to be completed the first of the week of July 10^th.

Harry Zhabilov, CSO of VIRO stated, "This is an exciting time for all of the individual Officers, Employees and consultants that are involved with not just the African Project but the SAGA transaction and expected transition to a National Market."

Barry Kostiner, CEO of Sagaliam, commented, "We are very enthusiastic about the continued advance of Virogentics developments in Africa. We are committed to the mission of empowering communities, promoting education, reducing poverty, and fostering social development. Bridging the pharmaceutical gap paves the way for a healthier and more equitable future for the continent. Enzolytics' two subsidiaries low-cost therapies are particularly helpful in communities that don't have the resources to fund expensive medications needed for the ongoing treatment of chronic conditions."